0001619087 us-gaap:IPOMember 2015-03-25 2015-03-25 0001619087 2015-03-01 2015-03-01 0001619087 us-gaap:RetainedEarningsMember 2016-03-31 0001619087 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001619087 us-gaap:RetainedEarningsMember 2015-12-31 0001619087 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001619087 us-gaap:CommonStockMember 2016-03-31 0001619087 us-gaap:CommonStockMember 2015-12-31 0001619087 us-gaap:IPOMember 2015-03-25 0001619087 us-gaap:SeriesEPreferredStockMember 2015-01-24 0001619087 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001619087 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001619087 stdy:StockOptionsEmployeesAndDirectorsMember stdy:AmendedAndRestated2009StockIncentivePlanMember 2016-01-01 2016-03-31 0001619087 stdy:StockOptionsEmployeesAndDirectorsMember stdy:AmendedAndRestated2009StockIncentivePlanMember 2015-01-01 2015-12-31 0001619087 stdy:StockOptionsEmployeesAndDirectorsMember stdy:AmendedAndRestated2009StockIncentivePlanMember 2016-03-31 0001619087 stdy:StockOptionsEmployeesAndDirectorsMember stdy:AmendedAndRestated2009StockIncentivePlanMember 2015-12-31 0001619087 stdy:StockOptionsDirectorsMember 2015-08-06 2015-08-06 0001619087 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember stdy:TwoThousandNinePlanMember 2016-03-31 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember stdy:TwoThousandNinePlanMember 2014-12-31 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember stdy:TwoThousandNinePlanMember 2009-06-18 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember stdy:TwoThousandNinePlanMember 2015-01-24 2015-01-24 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember stdy:TwoThousandNinePlanMember 2016-01-01 2016-03-31 0001619087 stdy:CardiomePharmaCorpAndCorrevioInternationalSarlMember 2016-01-01 2016-03-31 0001619087 stdy:LoanAgreementMember 2016-03-31 0001619087 stdy:LoanAgreementMember 2015-12-31 0001619087 stdy:CombinedOfficeOfChiefScientistAndIncubatorRadBiomedLtdMember 2005-01-01 2016-03-31 0001619087 us-gaap:IPOMember 2015-03-20 2015-03-25 0001619087 stdy:OfficeOfChiefScientistMember 2005-01-01 2016-03-31 0001619087 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001619087 stdy:NewOfficeMember stdy:SanRamonCaliforniaMember 2015-05-01 2015-05-31 0001619087 stdy:PreviousOfficeMember stdy:SanRamonCaliforniaMember 2013-09-30 2013-09-30 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember 2016-03-31 0001619087 stdy:StockOptionsAllInclusiveRecipientsMember 2016-01-01 2016-03-31 0001619087 2015-03-01 0001619087 2015-02-28 0001619087 us-gaap:ConvertiblePreferredStockMember 2015-03-19 0001619087 us-gaap:ConvertiblePreferredStockMember 2014-12-31 0001619087 stdy:CommercialBankMember us-gaap:SeriesDPreferredStockMember 2013-02-20 0001619087 2015-03-31 0001619087 2014-12-31 0001619087 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-03-31 0001619087 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001619087 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001619087 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-03-31 0001619087 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001619087 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001619087 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001619087 2016-03-31 0001619087 2015-12-31 0001619087 stdy:CommercialBankMember us-gaap:SeriesDPreferredStockMember 2013-02-20 2013-02-20 0001619087 2015-03-25 2015-03-25 0001619087 stdy:OfficeOfChiefScientistMember 2016-01-01 2016-03-31 0001619087 us-gaap:OverAllotmentOptionMember 2015-04-22 2015-04-22 0001619087 stdy:UnderwritersOverallotmentOptionExerciseMember 2015-04-22 2015-04-22 0001619087 stdy:OfficeOfChiefScientistMember us-gaap:MinimumMember stdy:FourthYearAndAfterRoyaltyTermMember 2016-01-01 2016-03-31 0001619087 stdy:OfficeOfChiefScientistMember us-gaap:MinimumMember stdy:FirstThreeYearsRoyaltyTermMember 2016-01-01 2016-03-31 0001619087 stdy:OfficeOfChiefScientistMember us-gaap:MaximumMember stdy:FourthYearAndAfterRoyaltyTermMember 2016-01-01 2016-03-31 0001619087 stdy:OfficeOfChiefScientistMember us-gaap:MaximumMember stdy:FirstThreeYearsRoyaltyTermMember 2016-01-01 2016-03-31 0001619087 stdy:ProductsForTreatmentOfPostsurgicalAndAcutePainInHomeSettingMember 2016-01-01 2016-03-31 0001619087 2015-01-01 2015-03-19 0001619087 country:IL 2012-06-30 2012-06-30 0001619087 stdy:CombinedOfficeOfChiefScientistAndIncubatorRadBiomedLtdMember 2016-01-01 2016-03-31 0001619087 stdy:LoanAgreementMember 2013-02-20 2013-02-20 0001619087 us-gaap:SeriesEPreferredStockMember 2015-01-24 2015-01-24 0001619087 stdy:CardiomePharmaCorpAndCorrevioInternationalSarlMember us-gaap:CollaborativeArrangementMember 2015-06-28 2015-06-28 0001619087 2015-01-01 2015-03-31 0001619087 2016-05-01 0001619087 2016-01-01 2016-03-31 iso4217:ILS xbrli:shares iso4217:USD xbrli:shares stdy:product xbrli:pure stdy:installment iso4217:USD xbrli:shares false --12-31 Q1 2016 2016-03-31 10-Q 0001619087 13585810 Yes Smaller Reporting Company SteadyMed Ltd. -4000 15000 9250000 mid-teens low teens 47075000 87000 1445966 32 0 28000 13000 P24M 1.25 401746 1463000 2 0.90 0.04 0.045 0.03 0.035 1308000 1308000 0 3.00 6.00 1.50 165452 165452 3000000 10191 3486 295697 405232 P10Y 7332

2333000

2825000

258000

1572000

1678000

91814000

92022000

208000

91000

63000

24000

4000

208000

174000

33000

1000

3000

35230000

29268000

32462000

25831000

124000

127000

184000

161000

6167000

48893000

31851000

25378000

6.14

711120

10191

0.01

5000000

50000000

13585810

34000

5945000

0.05

three-year constant maturity treasury rate

0.0525

1705000

1505000

426000

251000

61000

63000

85000

131000

P1Y11M9D

1226000

-40000

91000

52000

905000

1433000

-5433000

-6166000

-4.35

-0.46

182000

203000

123000

108000

-184000

106000

-375000

831000

331000

132000

34000

10000

3000

30000

P6M

P3Y

P17M

P4Y

35230000

29268000

5840000

6100000

843000

687000

230000

92000

222000

212000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> NOTE 1: -GENERAL   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> a. </td><td style="width:9pt;"></td><td align="left" valign="top"> SteadyMed Ltd. (the “Company”) was incorporated and is located in Israel, commenced its operations on June 15, 2005 and, together with its wholly-owned subsidiary, SteadyMed Therapeutics, Inc. (“Inc.”), and Inc.’s wholly-owned subsidiary, SteadyMed U.S. Holdings, Inc. (“Holdings”), is a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined high-margin specialty markets. The Company’s primary focus is to obtain approval in the United States for the sale of Trevyent® for the treatment of pulmonary arterial hypertension (“PAH”). The Company is also developing two products for the treatment of post-surgical and acute pain in the home setting. Its product candidates are enabled by its proprietary PatchPump®, which is a discreet, water resistant and disposable drug administration technology that is aseptically prefilled with liquid drug at the site of manufacture and pre-programmed to deliver an accurate, steady flow of drug to a patient, either subcutaneously or intravenously.</td></tr></table></div>   Inc. and Holdings are located in the United States, and commenced operations on January 1, 2012 and March 25, 2015, respectively. The principal executive officers of the Company are located in the offices of Inc. and Holdings, and Inc.’s and Holdings’ principal business activities are to provide executive management, treasury and administrative support functions to the Company.   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> b. </td><td style="width:9pt;"></td><td align="left" valign="top"> For the three months ended March 31, 2016, the Company incurred operating losses of $6,274 and negative cash flows from operating activities of $5,889. The Company’s current cash and cash equivalents will not be enough to support the Company’s future operations for the next 12 months. In 2016, management intends to raise significant additional capital by way of a private placement of debt and/or equity and/or a secondary public offering to allow the Company to continue as a going concern. While the Company believes in its ability to raise additional capital, there can be no assurance that it will be able to do so.</td></tr></table></div>   The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> c. </td><td style="width:9pt;"></td><td align="left" valign="top"> Initial Public Offering:</td></tr></table></div>   On March 19, 2015, a registration statement covering the public sale of 4,700,000 Ordinary Shares was declared effective by the U.S. Securities and Exchange Commission (“SEC”). Commencing on March 20, 2015, the Company’s ordinary shares began trading on the NASDAQ Stock Market operated under the ticker symbol “STDY”.   On March 25, 2015, the Company closed its IPO at a price of $8.50 per share and the aggregate net proceeds received by the Company from the offering were $34,696, net of underwriting discounts and commissions and offering expenses payable by the Company.   On April 22, 2015, the Company’s underwriters exercised a portion of their overallotment option pursuant to which they purchased 165,452 Ordinary Shares of the Company for $1,308, net of underwriters’ fees and commissions.   Upon the closing of the IPO, all shares of the Company’s outstanding Convertible Preferred Shares were automatically converted into 7,464,320 Ordinary Shares.   As of December 31, 2014, there were 711,120 outstanding warrants exercisable into Convertible Preferred Shares. Prior to the IPO, all but 10,191 warrants were exercised into Ordinary Shares. Of the exercised warrants, 295,697 were exercised for cash, and 405,232 were exercised on a cashless basis, resulting in the net exercise of 401,746 warrants (and 3,486 warrants were cancelled). Upon the closing of the IPO, the 10,191 warrants outstanding were automatically converted into warrants to purchase Ordinary Shares.   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> d. </td><td style="width:9pt;"></td><td align="left" valign="top"> On June 28, 2015, the Company entered into an Exclusive License and Supply Agreement (the “Agreement”) with Cardiome Pharma Corp. and Correvio International Sárl (hereinafter collectively referred to as “Cardiome”) pursuant to which an exclusive royalty bearing license to certain of the Company’s patents relating to Trevyent® (“License”) was granted to Cardiome in order to develop and commercialize Trevyent, if approved for the treatment of PAH in certain regions outside the United States; specifically, Europe, Canada and the Middle East (the “Regions”). The Company is obligated to perform certain services for Cardiome (“Services”) estimated to be completed by May 31, 2017. Cardiome is responsible for the regulatory submissions and approvals and commercialization of Trevyent in the Regions. In addition, the Company has agreed to supply Trevyent as finished goods to Cardiome upon commercialization of Trevyent® in the Regions (“Supply Services”).</td></tr></table></div>   Cardiome made a $3,000 upfront payment to the Company and the Agreement provides for future regulatory, third-party payor reimbursement approval and commercialization milestone payments to be achieved by Cardiome of up to $9,250 and a scaling royalty ranging from the low teens to mid-teens percent on future Trevyent sales by Cardiome in the Regions. In addition, there is a fixed price on finished goods to be supplied by the Company as part of the Supply Services. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

42726000

-6473000

47660000

-141000

-28000

-443000

-4906000

-5889000

-5556000

-6274000

-6544000

-6274000

103000

69000

5536000

6610000

-5536000

-6235000

35000

5200000

204000

634000

159000

178000

0.08

288000

321000

1500000

725000

40000000

11406000

176000

191000

145000

2583000

3247000

141000

4409000

4965000

323000

293000

132000

117000

-63301000

-69575000

375000

3000

36250000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 84.00%;margin-left:84.95pt;"> <tr> <td valign="bottom" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three months ended March 31, </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unaudited </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33  </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;padding:0pt;"> Marketing </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4  </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>174  </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>208  </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

91000

208000

P3Y

P7Y

1072879

55971

978655

744875

263711

200100

8990000

6670000

1249898

4.39

P5Y9M11D

P5Y6M11D

6670000

704647

3.93

P4Y4M2D

6670000

1244200

4.39

P5Y6M7D

7.45

3.00

5.60

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> NOTE 6: - SHAREHOLDERS’ EQUITY   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> a. </td><td style="width:9pt;"></td><td align="left" valign="top"> On January 24, 2015, the Company signed an addendum to the Series E Convertible Preferred Share purchase agreement to raise additional funds of $11,406, net of fees and expenses. Under the addendum, the Company issued 1,445,966 Series E Convertible Preferred Shares to its existing and new investors for a price of $8.49 per share.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> b. </td><td style="width:9pt;"></td><td align="left" valign="top"> On March 1, 2015, the Company effected a 7.75 for 1 forward split of its Ordinary Shares, by way of issuance and distribution of bonus shares without a change in nominal value of the Company’s outstanding Ordinary Shares.</td></tr></table></div>   For accounting purposes, this transaction was recorded as a share split and accordingly, all Shares, warrants to purchase Convertible Preferred Shares, options to purchase Ordinary Shares and loss per share amounts have been adjusted to give retroactive effect to this Share Split for all periods presented in these consolidated financial statements. Any fractional shares resulting from the Share Split will be rounded up to the nearest whole share.   In addition, the Company’s Board of Directors approved an increase the Company’s authorized Shares from 5,000,000 to 50,000,000.   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> c. </td><td style="width:10pt;"></td><td align="left" valign="top"> As described in Note 1c, on March 19, 2015, the Company completed its IPO by raising gross consideration of $40,000 for issuance of 4,700,000 Ordinary Shares for a price of $8.50 per share. The issuance costs in respect of the IPO transaction amounted to $5,200.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> d. </td><td style="width:10pt;"></td><td align="left" valign="top"> On April 22, 2015, the Company’s underwriters exercised their overallotment option pursuant to which they purchased 165,452 Ordinary Shares of the Company for $1,308 net of underwriters’ fees and commissions.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:56pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> e. </td><td style="width:10pt;"></td><td align="left" valign="top"> Stock-based compensation:</td></tr></table></div>   On June 18, 2009, a Stock Option Plan (the “2009 Plan”) was adopted by the Board of Directors of the Company, under which options to purchase up to 55,971 Ordinary Shares were reserved. Such pool was increased over the years and as of December 31, 2014, options to purchase up to 978,655 Ordinary Shares were authorized. The 2009 Plan was adopted in accordance with the amended sections 102 and 3(i) of Israel’s Income Tax Ordinance. Under the 2009 Plan, options to purchase Ordinary Shares of the Company may be granted to employees, advisors, directors, consultants and service providers of the Company or any subsidiary or affiliate. The default vesting schedule is up to three years, subject to the continuation of employment or service. Each option may be exercised into Ordinary Shares during a period of seven years from the date of grant, unless a different term is provided in the option agreement. On April 30, 2013, the 2013 Stock Incentive Sub Plan (the “2013 Sub Plan”) was adopted by the Board of Directors of the Company, which set forth the terms for the grant of stock awards to Inc.’s employees or US non employees. On January 25, 2015, the Board of Directors reserved an additional 1,072,879 Ordinary Shares out of its authorized and unissued share capital for future option grants under the 2009 Plan.   On February 20, 2015, the Company’s Board of Directors approved the replacement of the 2009 Plan and 2013 Sub Plan by adopting the Amended and Restated 2009 Stock Incentive Plan. This action was approved by the shareholders on March 1, 2015.   During year ended December 31, 2015, the Company’s Board of Directors approved grants of 263,711 options to certain employees to purchase the Company’s Ordinary Shares at an exercise price of $3.00 to $7.45.   On August 6, 2015, the Company’s shareholders approved among other actions, grants of 200,100 options to its directors to purchase the Company’s Ordinary Shares at an exercise price of $5.60, at the Company’s 2015 annual general meeting of shareholders.   Transactions related to the grant of options to employees and directors under the Amended and Restated 2009 Stock Incentive Plan during the three months period ended March 31, 2016 (unaudited), were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 84.00%;margin-left:84.95pt;"> <tr> <td valign="bottom" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average exercise price </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average remaining contractual life </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Aggregate intrinsic value </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> options </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (years) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;background-color: #CCEEFF;padding:0pt;"> Options outstanding at January 1, 2016 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,249,898  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.39  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.78  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.99  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;"> Options granted </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;background-color: #CCEEFF;padding:0pt;"> Options expired </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;"> Options exercised </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;"> Options outstanding at end of the period </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,249,898  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.39  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.53  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.67  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;"> Options vested and expected to be vested at end of the period </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,244,200  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.39  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.52  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.67  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;"> Options vested at end of the period </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>704,647  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.93  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.34  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.67  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:33.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the deemed fair value of the Company’s ordinary shares on the last day of the three months period ended March 31, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on March 31, 2016. This amount is impacted by the changes in the fair market value of the Company’s shares.   As of March 31, 2016, the Company has 744,875 Ordinary Shares available for future grant under the Amended and Restated 2009 Plan.   As of March 31, 2016, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $1,226, which is expected to be recognized over a weighted average period of approximately 1.94 years.   The total compensation cost related to all of the Company’s equity-based awards, recognized during the three months period ended March 31, 2016 and 2015 (unaudited) was comprised as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 84.00%;margin-left:84.95pt;"> <tr> <td valign="bottom" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three months ended March 31, </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unaudited </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33  </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;padding:0pt;"> Marketing </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4  </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>174  </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.24%;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>208  </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.42%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

8.49

8.50

13585810

28547000

91814000

34000

-63301000

22481000

92022000

34000

-69575000

7.75

7464320

4700000

34696000

988000

1503708

13585810